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Introduction 
Sutherlandia frutescens (L.)  R.Br.  (syn.  Lessertia  frutescens (L.) Goldblatt and J.C. 
Manning) is an indigenous medicinal plant extensively used in South Africa to treat a 
variety of health conditions. It is a fairly widespread, drought-resistant  plant  that  grows  in  
the  Western,  Eastern,  and Northern Cape provinces and some areas of KwaZulu-Natal, 
varying in its chemical and genetic makeup across these geographic areas.1 Sutherlandia 
is widely used as a traditional medicine. Extensive scientific studies are being carried out on 
the safety, quality, and the efficacy of this medicinal plant to validate the traditional claims, 
elucidate the bioactive constituents, and conduct clinical trials. This has resulted in a 
unique situation in South Africa’s history, where traditional knowledge and science intersect 
to provide insight into this popular plant. This photoessay attempts to illustrate the 
interlinkage of science with the indigenous knowledge of traditional healers, the local 
knowledge of people who care for the sick, product development, and innovation agenda of 
the country as it relates to this plant. The essay shows how S. frutescens, as a medicinal 
plant, and the study of its pharmacologic components are represented and understood 
differently, yet with a similar aim: to enhance its safety. The essay explores the plant as 
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botanical entity, its local uses and therapeutic properties, and the science related to ongoing 
phase IIa and IIb clinical trials. 
 
 
 
The Botanical Entity 
The Cape Floristic Region (one of the richest areas for plants in the world) is home to 
Sutherlandia frutescens. Specifically, Sutherlandia is found in the Fynbos Biome, home to the 
largest variety of plant species. S. frutescens belongs to the class Magnoliopsida, order 
Fabales, genus Sutherlandia, and species frutescens.  It was recently proposed that S.  
frutescens be transferred to the genus Lessertia D.C. on the basis of the assumption that 
Sutherlandia represents an adaption to bird pollination. However, this proposed 
reclassification is contentious, requiring more morphological and genetic evidence.1 
 
S. frutescens is a medium-sized shrub, with fine grayish-green leaves and red, butterfly-
shaped flowers. Its seedpods are large and balloon-like with a slightly reddish tint (Figs. 1 and 
2). It is a medicinal plant, mostly harvested wild, but it is also grown in community gardens 
and commercially on a small number of farms. The plant has more than 25 recorded names. 
Some are related to the color and shape of the plant’s flowers, such as kalkoenbos (turkey 
bush), hoenderbelletjie (the wattle of a cockerel), eendjie (duckling); to its seedpods, such as 
blaasbossie (for its balloon-like pods) and blaas-ertjie (balloon-like pea); or to the 
appearance (unwele [hair]) or taste (bitterbos [bitter bush]) of its downy leaves. Many of its 
names also refer to medicinal use, such as kankerbos (cancer bush; Afrikaans), insiswa 
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(dispels darkness; Zulu), phetola (to change; Tswana), and lerumo lamadi (spear of the 
blood; North Sotho). 
 
The Traditional Uses of Sutherlandia 
In South Africa, Sutherlandia is used by an array of healers, such as herbalists (inyanga) (Fig. 
3), diviners (isangoma), bush doctors (bossiedokters), Rastafarians, alternative and allopathic 
medicine practitioners, and lay people.2–6 S. frutescens has long been used as a garden 
plant for flower arrangements, but this bitter-tasting plant is best known for its medicinal 
values. First records about its use came from Dutch colonists in the Cape, who probably 
came to know it through interaction with the local San and Khoi.3 The original inhabitants 
of the Cape, the Khoi San and Nama people, used decoctions made from Sutherlandia to 
wash wounds and to bring down fevers.7 Not surprisingly, S. frutescens is today still one of 
the most commonly used medicinal plants in the Western Cape.8 It is also sold in muthi 
(medicine) markets and in amayeza (medicine) shops in other parts of the country. 
 
Preparation and Use 
The aerial parts of the plant (stems, leaves, flowers, and pods), the roots, or only the leaves 
are usually used to make the infusions and decoctions. A decoction of Sutherlandia is used 
to wash wounds and the eyes and to reduce fevers,7 and the infusions from the leaves and 
stems are used to treat cancers, fever, diabetes, kidney and liver problems, rheumatism, 
and stomach ailments.9 The plant is also used for a diversity of symptoms and conditions, 
such as depression and stress; as a tonic; to purify the blood and wounds; to treat skin 
conditions and inflammation; to enhance appetite and prevent wasting; as an emetic; and 
to treat influenza, hemorrhoids, urinary tract infections, back pain, and gonorrhea.1 
 
Traditional healers prepare the decoctions according to the type of disease indicated by the 
patient. Their preparation ranges from using the leaves, flowers, stems, and roots for 
different ailments.10 The traditional healers collect fresh plant materials, dry them, and 
then stamp or mash them into powder between two stones (Figs. 4 and 5). The preparation 
is then usually infused in hot or boiling water, left to cool, and given to the sick person. 
 
Currently, Sutherlandia is available in various dosage forms, such as capsules and 
tablets (containing Sutherlandia raw material in powdered form), gels for topical 
application, creams, liquid extracts, and ointments and is found in pharmacies and 
herbal shops.1 Commercial Sutherlandia tablets gained popularity as an herbal product 
for the treatment of muscle-wasting  effects in  patients with HIV/AIDS because of a 
marked improvement in quality of life.1,8 To meet the demand for this important 
medicinal plant, several commercial farms exist in South Africa. 
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Pharmacology of Sutherlandia frutescens 
The therapeutic properties of Sutherlandia are based on its ability to help the human body to 
mobilize its own immunologic and physiologic resources to help combat diseases and fight 
mental and emotional stress.11 Several reviews have been published on the pharmacologic 
activities of S. frutescens.1,8,12 In vitro and in vivo studies carried out on the leaf and whole 
plant extracts have provided evidence of its antiproliferative, antiviral, antistress, antidiabetic, 
anti-inflammatory, antimutagenic, antibacterial, antioxidant, and antithrombotic properties, 
thus validating the traditional claims.1 
 
Cancer 
With  regard  to  the  anticancer  activity  of  Sutherlandia, studies on the effect of the 
aqueous extract on cell number, morphology, cell cycle progression, and cell death using 
MCF-7 (human breast adenocarcinoma) and MCF-12A (human nontumorigenic epithelial 
mammary gland cells) have been carried out.13 A dose-dependent decrease in malignant cell 
number compared with control and a difference in the mechanism of action of 
Sutherlandia extract on MCF-7 cells compared with MCF-12A cells was observed. The 
nephrotoxic and apoptotic effect of Sutherlandia on kidney cell lines (LLC-PK1, proximal 
convoluted tubule epithelium; MDBK, distal convoluted tubule epithelium) revealed that at 
concentrations higher than 6 mg/ml, the aqueous extract of S. frutescens were not 
cytotoxic and the extract possessed the potential to increase oxidative stress, promote 
apoptosis, and alter the integrity of mitochondrial membranes in the renal tubules.14 
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Stress 
A study on the chronic intermittent immobilization stress in adult male Wistar rats fed with 
aqueous extract of Sutherlandia for 28 days showed a reduction in the corticosterone response 
to chronic stress.15 Extracts of Sutherlandia have also been found to inhibit cytochrome 
P450, which catalyzes the synthesis of cortisol and its precursors.11 Also, daily treatment 
with Sutherlandia decreased markers of muscle atrophy and inhibited apoptosis in chronic 
restrained stressed rat models.16 These studies demonstrated the indigenous use of 
Sutherlandia as a stress-relieving medicinal plant. 
 
Neurologic diseases 
Sutherlandia also acts as an antidepressant; as a natural treatment for children with 
convulsions and epilepsy;17 and as a supportive treatment for mental and emotional stress, 
including anxiety.17 
 
Diabetes 
The antidiabetic effects of Sutherlandia were observed in animal studies.18,19 Sutherlandia 
normalized insulin levels and glucose uptake in peripheral tissues and suppressed intestinal 
glucose uptake, with no weight gain, in treated rats.18 Antidiabetic action of Sutherlandia in 
rats with streptozotocin-induced diabetes showed the ability of this plant to induce signifi   
hypoglycemic effect in streptozotocin-treated rats.19 The diabetic rats treated with 
Sutherlandia maintained their reduced blood glucose levels longer than did their 
chlorpropamide-treated counterparts.19Antioxidant activity was demonstrated by the reduction 
of free radicals, and suppression of lipopolysaccharides stimulated nitric oxide production.20  
In this manner, Sutherlandia might also play a role in combating autoimmune diabetes by 
inhibiting the production of nitric oxide and subsequent damage to the pancreatic b cells.20 
 
HIV 
A study showed that the aqueous extract of Sutherlandia leaf stimulated reverse 
transcriptase activity in the presence of tannin, whereas no activity was recorded for the 
HIV-2 protease. In contrast, the inhibitory effect of various extracts of Sutherlandia against 
HIV-1 reverse transcriptase and22,23 integrase exhibited little or no activity. 
 
Chemical Composition 
The mechanism of action of S. frutescens for these disease and conditions is not known, but 
several attempts are being made to understand how this plant works. Various chemical 
compounds that might be responsible for the activity of Sutherlandia have been isolated. 
These include triterpenoids, saponins, flavonoids, c-aminobutyric acid (GABA) and pinitol.1 
The latter compound may be responsible for the antidiabetic effects and the reversal of 
muscle-wasting effects in HIV patients, as it has been found to possess insulin-like 
properties.24 Pinitol also stimulates glucose uptake as well as translocation of the glucose 
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transporter 4 (GLUT4) to the plasma membrane25and protects against liver damage and 
hepatotoxicity induced by d-galactosamine (a model system for hepatitis).26 
 
l-canavanine (2-amino-4-guanidinooxybutyric acid) is the most important nonprotein amino 
acid found in the leaves of  Sutherlandia.  l-canavanine is  a  structural  analogue  of l-
arginine and a natural insecticide. Its close similarity to arginine means it can interfere with 
arginine metabolism and be incorporated into proteins, leading to the formation of 
dysfunctional proteins.27 Canavanine has also been reported to be a potent anticancer 
agent,28,29 as well as having anti-viral activity against influenza and retroviruses.30 
Recent reports also showed that canavanine was a potent inhibitor of nitric oxide synthase 
and could be useful in the treatment of septic or endotoxic shock.31,32 Significant amounts 
of GABA have also been found in Sutherlandia. This compound is an inhibitory 
neurotransmitter and could explain the use of Sutherlandia for the treatment of stress and 
anxiety.1 
 
Other chemical compounds, such as cycloartane glycosides33 and flavonol glycosides,34 
have recently been isolated from Sutherlandia, which may play a role in the bioactivity of this 
herbal medicine. Figure 6 shows a chemical profile of the flavonoid constituents of dried S. 
frutescens. Flavonoids have many health-protecting effects, including anticancer and 
antiviral35 and antiosteoporotic and anticardiovascular activities36 and anti-inflammatory 
and antiallergic,37 antimicrobial, antiproliferative, chemoprotective, and antioxidant38 
effects, that may explain or support the traditional claims of S. frutescens. However, none of 
the above-mentioned chemical constituents of this plant have been conclusively linked to its 
therapeutic effect, validating the suggestion that the medicinal potential of Sutherlandia 
might be as a result of the synergism between the compounds found in the plant.20 
 
In the last few years, most of the research carried out on S. frutescens has been aimed at in 
vitro propagation methods as a tool to meet the commercial demands for this important 
indigenous medicinal plant. Researchers have focused on an efficient in vitro plant 
regeneration system in order to conserve biodiversity. To this effect, several studies have 
been undertaken on the molecular and genetic modifications of Sutherlandia to regulate 
and maximize the yield of its bioactive constituents.39–42 
 
Safety of Sutherlandia 
No serious adverse effects have been reported since ancient times. However, symptoms 
such as occasional dry mouth, loose stools, or mild diuresis and slight dizziness have been 
observed in weak patients when the herb is administered on an empty stomach.12 
Sutherlandia is used traditionally   during   pregnancy   with   no   adverse   effect; however, 
scientific data do not exist to validate the use of the plant in pregnant women.12 The dosage 
http://repository.uwc.ac.za
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dispensed by traditional healers depends on the severity of the illness, age of the patient, and 
the nature of the complaint. Several reports of varying dosages exists in literature.1 
 
However, a scientific study recommended daily dose of Sutherlandia leaf powder is 9.0 
mg/kg body weight, which is equivalent to two Sutherlandia tablets per day, each containing 
300 mg of Sutherlandia dried leaf powder each. This dosage was drawn from the toxicology 
study on vervet monkeys (Chlorocebus aethiops), which further indicated that nine times the 
recommended dosage (81 mg/kg) administered daily for 3 months showed no significant 
changes to relevant hematologic, biochemical, and physiologic measures.43 A recent phase I 
double-blind, placebo-controlled study (protocol TI-CIPS001) conducted by the International 
Centre for Indigenous Phytotherapy Studies (TICIPS) through the South African Herbal 
Science and Medicine Institute (SAHSMI) at the University of the Western Cape on healthy 
individuals reported that 400 mg of leaf powder capsule twice a day for 3 months was 
tolerated without adverse effects.44 The South African Ministry of Health encouraged the use 
of S. frutescens for the treatment of patients with AIDS.12 Many patients therefore take 
traditional herbal medicines in conjunction with their modern antiretroviral medication, 
without recourse to the potential of drug–herb interactions. 
 
Several studies on the interaction between antiretroviral drugs, such as nevirapine and 
atazanavir, and Sutherlandia  extracts and its bioactives have been reported.45–47 In one of 
these studies, although l-canavanine increased the bioavailability and ultimately interaction 
with nevirapine in Caco-2 cells, no such effect was observed with the aqueous extract of 
Sutherlandia.45 Long-term administration of S. frutescens extracts to male Sprague-
Dawley rats for 5 days significantly reduced pharmacokinetic parameters (area under the 
curve and maximum concentration) of nevirapine.46 Minocha and colleagues concluded 
from their preclinical results that co-administration of Sutherlandia along with low-
therapeutic- index prescription drugs could lead to herb–drug interactions as well as 
limited efficacy of such drugs.46 
 
The aqueous and methanolic extracts of S. frutescens, as well as the terpenoid and flavonol 
glycoside fractions, varied in their influence on the accumulation of atazanavir by Caco-2 cells 
and also its metabolism in human liver microsomes. 
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Although the aqueous extract reduced the absorption of atazanavir in the Caco-2 cells and 
the metabolism in human liver microsomes, the opposite was observed for the terpenoid 
fraction.47 These herb–drug interactions may have important implications for the safety 
and efficacy of anti-retrovirals in immunocompromised patients. 
 
Sutherlandia HIV/AIDS Clinical Trials: the Meeting of Science and 
Traditional Knowledge 
The popularity of herbal medicines has led to increasing concerns over their safety, quality, 
and efficacy. To this end, clinical trials have been conducted worldwide to ascertain the 
safety and efficacy of these herbal products using human participants. With regard to S. 
frutescens, several caregivers, such as Anne Hutchings, have treated HIV patients with 
Sutherlandia and other herbs weekly at Ngwelezana Hospital’s AIDS clinic in northern 
KwaZulu-Natal. She observed that when taken with a proper diet, Sutherlandia improves 
quality of life and might be significant in delaying the need for antiretroviral therapy.48 
 
Reports such as this have prompted the funding of two separate trials by the governments 
of the United States and South Africa to clinically validate the claims of safety and efficacy. 
The National Institute of Health, through TICIPS, funded phase I and II clinical trials on the 
safety and efficacy of Sutherlandia leaf powder capsules in healthy and HIV-infected 
patients. Results of the phase I study have provided evidence of the safety of Sutherlandia in 
healthy people.44 The South African government, through the Department of Science and 
Technology, is sponsoring a phase II trial to be conducted by SAHSMI using formulated 
S. frutescens capsules. This proposed trial aims to determine the safety and the effect of the 
formulated capsules on the markers of HIV progression in HIV patients. The study also aims 
to improve understanding of the pharmacokinetics of the formulated Sutherlandia 
capsules in the patients. 
 
Intellectual Property Right Issues Regarding Sutherlandia 
Acknowledging the value of indigenous knowledge in South Africa has brought to the fore the 
issue of protecting it and ensuring that knowledge holders are compensated for their 
contribution to the development of commercially traded products. To this end, South Africa is 
making a lot of effort to protect and encourage indigenous communities to use their natural 
resources and for its citizens to value traditional knowledge and innovation. However, 
identifying the ownership of the traditional knowledge of Sutherlandia as an antiviral agent 
has proved to be difficult. Sutherlandia has a history of medicinal use across several 
communities in South Africa. However, SAHSMI, through the Technology Transfer Office of 
the University of the Western Cape, is participating in discussions on bio-prospecting and 
intellectual property rights concerning use of Sutherlandia capsules in clinical trials for 
HIV/AIDS. Issues raised in this discussion include benefit sharing, bio-prospecting, and 
intellectual property rights. 
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Conclusion 
S. frutescens is increasingly understood and studied as a phytomedicine that can potentially 
be used for people who are HIV positive but who do not yet qualify for antiretroviral 
treatment (i.e., to fill the treatment gap). This can happen only if the clinical trials show 
that Sutherlandia is safe, is of good quality, and demonstrates efficacy. At the same time, 
greater collaboration between traditional health practitioners and scientists enhances 
insights into the use, preparation, therapeutic possibilities, and pharmaceutical make-up of 
this plant medicine. In this way, traditional knowledge and science intersect in new and 
original ways. 
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